Wegovy goes oral
The FDA has approved oral semaglutide as the first GLP‑1 pill for weight loss, a shift that mirrors injectable Wegovy results — the Phase III OASIS 4 program reported a mean weight loss of 13.6% at 64 weeks, which underpinned approval and raised expectations for broader access. Novo Nordisk is also rolling out a higher-dose Wegovy HD 7.2 mg in the U.S. and launching a subscription distribution program through telehealth partners like Ro, WeightWatchers and LifeMD to expand availability. (ajmc.com) (appliedclinicaltrialsonline.com) (pharmexec.com) (managedhealthcareexecutive.com)
Most weight-loss drugs went mainstream by asking people to use a weekly injector pen. Novo Nordisk’s new version asks for a morning glass of water instead: the Food and Drug Administration cleared Wegovy tablets in December 2025 as the first pill in this drug class approved for chronic weight management in adults. (ajmc.com) The drug inside the pill is semaglutide, a lab-made copy of a gut hormone called glucagon-like peptide-1 that tells the brain you’ve eaten and slows how fast food leaves the stomach. That is why people on these drugs usually report less hunger, smaller portions, and more nausea than on older diet pills. (novonordisk.com) Turning that kind of drug into a tablet took years because the stomach treats protein-like medicines the way it treats breakfast. Novo Nordisk says the basic problem was getting semaglutide through stomach acid and digestive enzymes without having it broken down first. (novonordisk.com) That is also why the pill comes with stricter instructions than the shot. The prescribing information says Wegovy tablets have to be taken on an empty stomach with a small amount of water, and patients must wait at least 30 minutes before food, other drinks, or other oral medicines. (accessdata.fda.gov) The approval rested on a late-stage study called OASIS 4 that enrolled 307 adults with obesity or overweight and no diabetes. After 64 weeks, the average weight change was minus 13.6% on oral semaglutide versus minus 2.2% on placebo, both alongside lifestyle counseling. (ajmc.com) A stricter analysis that counted only people who stayed on treatment as assigned came out even stronger. In that version, average weight loss reached 16.6% with the pill, which is why Novo Nordisk has been comparing the tablet to the original Wegovy injection rather than to older oral obesity drugs. (ajmc.com) The label is not just about the scale. The Food and Drug Administration also cleared the tablet to reduce the risk of major cardiovascular events, including heart attack and stroke, drawing on the broader semaglutide evidence base that Novo tied to the approval package. (appliedclinicaltrialsonline.com) Novo Nordisk moved quickly from approval to rollout. Reports in early January 2026 said U.S. patients could start getting the oral version through retail pharmacies and telehealth channels, with the first starter dose available January 5 and more strengths following that week. (pharmexec.com) (rheumatologyadvisor.com) The company is widening the menu on the injection side at the same time. On March 19, 2026, the Food and Drug Administration approved Wegovy HD, a 7.2 milligram shot for certain adults, and said the filing was cleared in 54 days under its Commissioner’s National Priority Voucher pilot program. (fda.gov) Then on March 31, 2026, Novo Nordisk added a multi-month subscription program for Food and Drug Administration-approved Wegovy in the United States, saying the plan could save patients up to $1,200 a year. The same access push has leaned on telehealth partners including Ro, WeightWatchers, and LifeMD, which gives Novo more ways to sell the same medicine to people who do not want a weekly needle or a traditional clinic visit. (novonordisk-us.com) (rheumatologyadvisor.com)
